RT Journal Article
SR Electronic
T1 The impact of relaxing interventions on human contact patterns and SARS- CoV-2 transmission in China
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.03.20167056
DO 10.1101/2020.08.03.20167056
A1 Juanjuan Zhang
A1 Maria Litvinova
A1 Yuxia Liang
A1 Wen Zheng
A1 Huilin Shi
A1 Alessandro Vespignani
A1 Cecile Viboud
A1 Marco Ajelli
A1 Hongjie Yu
YR 2020
UL http://medrxiv.org/content/early/2020/08/04/2020.08.03.20167056.abstract
AB Non-pharmaceutical interventions to control COVID-19 spread have been implemented in several countries with different intensity, timing, and impact on transmission. As a result, post-lockdown COVID-19 dynamics are heterogenous and difficult to interpret. Here we describe a set of contact surveys performed in four Chinese cities (Wuhan, Shanghai, Shenzhen, and Changsha) during the pre-pandemic, lockdown, and post-lockdown period to quantify the transmission impact of relaxing interventions via changes in age-specific contact patterns. We estimate that the mean number of contacts increased 5%-17% since the end of the lockdown but are still 3-7 times lower than their pre-pandemic levels. We find that post-lockdown contact patterns in China are still sufficiently low to keep SARS-CoV-2 transmission under control. We also find that the impact of school interventions depends non-linearly on the share of other activities being resumed. When most community activities are halted, school closure leads to a 77% decrease in the reproductive number; in contrast, when social mixing outside of schools is at pre-pandemic level, school closure leads to a 5% reduction in transmission. Moving forward, to control COVID-19 spread without resorting to a lockdown, it will be key to dose relaxation in social mixing in the community and strengthen targeted interventions.One Sentence Summary Social contacts estimated in the post-lockdown period in four large Chinese cities are not sufficient to sustain local SARS-CoV-2 transmission.Competing Interest StatementH.Y. has received research funding from Sanofi Pasteur, GlaxoSmithKline, Yichang HEC Changjiang Pharmaceutical Company, and Shanghai Roche Pharmaceutical Company.Funding StatementH.Y. acknowledges financial support from the National Science Fund for Distinguished Young Scholars (No. 81525023), National Science and Technology Major Project of China (No. 2018ZX10201001-010, No. 2018ZX10713001-007, No. 2017ZX10103009-005).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval was obtained from the institutional review board of the School of Public Health, Fudan University (IRB#2020-01-0801-S2).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data and code is available in the main text or the supplementary materials or it will be made available on GitHub and Zenodo upon acceptance.